The efficacy and safety of rituxima

The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis

Zhihong Zhao
Guixiang Liao
Yongqiang Li
Shulu Zhou
Hequn Zou

Affiliations
Contributions
Corresponding author

Scientific Reports
5,
Article number:
8219
doi:10.1038/srep08219

Received
19 September 2014
Accepted
02 January 2015
Published
03 February 2015

Article tools

PDF
PDF
Citation
Reprints
Rights & permissions
Article metrics

Rituximab is considered to be a promising drug for treating childhood refractory nephrotic syndrome. However, the efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome remain inconclusive. This meta-analysis aimed to investigate the efficacy and safety of rituximab treatment compared with other immunosuppressive agents in children with refractory nephrotic syndrome. Three randomized controlled trials and two comparative control studies were included in our analysis. The included studies were of moderately high quality. Compared with other immunotherapies, rituximab therapy significantly improved relapse-free survival (hazard ratio = 0.49, 95% confidence interval [CI], 0.26–0.92, P = 0.03). Rituximab also achieved a higher rate of complete remission (risk ratio,1.62; 95% CI, 0.92 to 2.84, P = 0.09) and reduced the occurrence of proteinuria (mean difference = −0.25, 95% CI = −0.29 to −0.21, P < 0.00001); however, a more targeted rituximab treatment did not significantly increase serum albumin levels and did not significantly reduce adverse events. Rituximab might be a promising treatment for childhood refractory nephrotic syndrome; however, the long-term effects and cost-effectiveness of rituximab treatment were not fully assessed, and there were limited studies that evaluated the clinical benefits of a concurrent infusion of rituximab plus a steroid compared with an infusion of rituximab only. Additional studies are required to address these issues.

Hasil (Bahasa Indonesia) 1:

Efektivitas dan keamanan rituximab dalam mengobati Sindrom nefrotik refrakter masa kanak-kanak: meta-analisis Zhihong Zhao Guixiang Liao Yongqiang Li Shulu Zhou Hequn Zou Afiliasi Kontribusi Sesuai penulis Laporan ilmiah 5,Nomor artikel: 8219 Doi:10.1038 / srep08219Menerima 19 September 2014 Diterima 02 Januari 2015 Diterbitkan 03 Februari 2015 Pasal tools PDF PDF Kutipan Cetak ulang Hak & izin Artikel metrikRituximab is considered to be a promising drug for treating childhood refractory nephrotic syndrome. However, the efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome remain inconclusive. This meta-analysis aimed to investigate the efficacy and safety of rituximab treatment compared with other immunosuppressive agents in children with refractory nephrotic syndrome. Three randomized controlled trials and two comparative control studies were included in our analysis. The included studies were of moderately high quality. Compared with other immunotherapies, rituximab therapy significantly improved relapse-free survival (hazard ratio = 0.49, 95% confidence interval [CI], 0.26–0.92, P = 0.03). Rituximab also achieved a higher rate of complete remission (risk ratio,1.62; 95% CI, 0.92 to 2.84, P = 0.09) and reduced the occurrence of proteinuria (mean difference = −0.25, 95% CI = −0.29 to −0.21, P < 0.00001); however, a more targeted rituximab treatment did not significantly increase serum albumin levels and did not significantly reduce adverse events. Rituximab might be a promising treatment for childhood refractory nephrotic syndrome; however, the long-term effects and cost-effectiveness of rituximab treatment were not fully assessed, and there were limited studies that evaluated the clinical benefits of a concurrent infusion of rituximab plus a steroid compared with an infusion of rituximab only. Additional studies are required to address these issues.